The European Medicines Agency (EMA) on Monday kicked off operations at its temporary premises at the Spark building in Amsterdam Sloterdijk after moving out of its Canary Wharf office in London on 1 March.
EMA says it is also working with Dutch authorities to finish readying its temporary premises ahead of 30 March, when the agency’s seat officially switches from London to Amsterdam.
“By Monday 18 March, when EMA will be settled in the Spark building, close to 350 staff members will have already relocated to the Netherlands,” EMA says. However, to accommodate staff members’ international move, the agency is allowing some staff to telework from London until the second half of 2019.
That said, the agency says it still anticipates losing roughly 25% of its staff in the move.
Until its permanent offices are ready, EMA will operate out of the Spark building and use that location for all face-to-face meetings. However, the agency says it will be using the address of its permanent offices in Amsterdam Zuidas as its official and mailing address from now on.
First published in Regulatory Focus™ by the Regulatory Affairs Professionals Society, the largest global organization of and for those involved with the regulation of healthcare products. Click here for more information.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 45,000+ biopharma pros who read Endpoints News by email every day.Free Subscription